» Articles » PMID: 8895520

Lack of Class I HLA Expression in Neuroblastoma is Associated with High N-myc Expression and Hypomethylation Due to Loss of the MEMO-1 Locus

Overview
Journal Oncogene
Date 1996 Oct 17
PMID 8895520
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Class I HLA expression is low in neuroblastoma tumours and cell lines. We have recently mapped a modifier of methylation for HLA-C (MEMO-1) to chromosomal bands 1p35-36.1, a region deleted in many neuroblastomas. Hypomethylation of HLA-C is strongly correlated with allelic loss of the MEMO-1 locus. Here, we show that loss of MEMO-1 is associated with hypomethylation of both the 5' and 3' regions of class I HLA loci. We next investigated the relationship between methylation and expression of class I HLA in 28 cell lines of neuroectodermal tumours. Cell lines with hypermethylated HLA-C and HLA-A loci have relatively high expression, while most cell lines with hypomethylated loci have no or a reduced expression. It was reported earlier that high expression of c- or N-myc can suppress class I HLA expression. Remarkably, also N-myc amplification in neuroblastomas is associated with allelic loss of 1p35-36. Therefore, we have analysed the relationships between allelic loss of the MEMO-1 locus, class I HLA methylation and expression, and N-myc amplification and expression. This study shows a tight inter-relationship between these phenomena. Our data suggest a model in which hypomethylation of class I HLA due to loss of the MEMO-1 locus and high N-myc expression could collaborate in the down-regulation of class I HLA expression.

Citing Articles

Impaired Antitumor Immune Response in -amplified Neuroblastoma Is Associated with Lack of CCL2 Secretion and Poor Dendritic Cell Recruitment.

Kacher J, Manches O, Aspord C, Sartelet H, Chaperot L Cancer Res Commun. 2023; 2(7):577-589.

PMID: 36923280 PMC: 10010397. DOI: 10.1158/2767-9764.CRC-21-0134.


Spotlight on TAP and its vital role in antigen presentation and cross-presentation.

Mantel I, Sadiq B, Blander J Mol Immunol. 2022; 142:105-119.

PMID: 34973498 PMC: 9241385. DOI: 10.1016/j.molimm.2021.12.013.


The MYC oncogene is a global regulator of the immune response.

Casey S, Baylot V, Felsher D Blood. 2018; 131(18):2007-2015.

PMID: 29514782 PMC: 5934797. DOI: 10.1182/blood-2017-11-742577.


Aberrant DNA methylation in human cancers.

Li W, Chen B J Huazhong Univ Sci Technolog Med Sci. 2013; 33(6):798-804.

PMID: 24337838 DOI: 10.1007/s11596-013-1201-0.


The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer.

Mimura K, Shiraishi K, Mueller A, Izawa S, Kua L, So J J Immunol. 2013; 191(12):6261-72.

PMID: 24244023 PMC: 3856928. DOI: 10.4049/jimmunol.1301597.